President’s Message
Autoantibody Testing Saves Diagnostic Refugees
Proteobridge was established as an AIST technology transfer venture by Dr. Kumagai (currently President) and Dr. Goshima (currently Vice President) of the then National Institute of Advanced Industrial Science and Technology (AIST), with the aim of solving the problem of difficulty in autoimmune disease diagnosis.
Our company contributes to the elucidation of the pathogenesis of autoimmune diseases and the creation of new diagnostic methods. We continue to promote research on autoantibodies and autoimmune diseases in collaboration with physicians and researchers around the world by utilizing our unique protein array technology.
Connective tissue disease is a group of autoimmune diseases that are not easily diagnosed in the early stages, and many patients visit numerous hospitals for diagnosis.
The reason for the high number of difficult to diagnose people is that there are many types of autoantibodies associated with the condition and many designated intractable diseases whose pathophysiology is still being clarified, making diagnosis difficult even for physicians. Although the diagnostic criteria include autoantibody testing, there are only a few types of autoantibodies that can be measured by insurance, and in many cases, “all negative” results are obtained in hospital tests.
To solve this problem, all autoantibodies related to the pathology must be measured simultaneously. We have developed and launched the research test A-Cube®, which is now used in more than 85% of hospitals with specific functions. We will continue to contribute to the elucidation of the pathophysiology of autoimmune diseases and to the relief of refugees from diagnosis around the world by promoting the use of this test.
Corporate Identity
Building Proteomics Bridges to a Healthy Tomorrow
QUALITY POLICY
Quality Policy
We are a bio-venture company from the National Institute of Advanced Industrial Science and Technology (AIST) and focus on the analysis of autoantibodies in blood. We promote the following quality policy to become a company trusted by our customers.
- We aim to be the world leader in autoantibody research, applying cutting-edge technology to medical care and diagnostics.
- We provide high-quality products and services that meet customer and regulatory requirements.
- We will continuously improve the effectiveness of our quality management system through communication with our customers and partners.
December 1, 2021
Proteobridge Corporation
Representative Director Ryo Kumagai
About Us
| Date of Establishment | January 5, 2018 (December 31, 2018) |
| capital stock | 50,000,000 yen |
| Location | Headquarters & Research Centers Aomi 2-4-7, Aomi, Koto-ku, Tokyo 135-0064, Japan 2-4-7 Aomi, Koto-ku, Tokyo National Institute of Advanced Industrial Science and Technology (AIST) Rinkai Center Annex 5108 |
| Number of Employees | 20 |
| Business | A-Cube® Business HuPEX® Business Autoantibody database project (under development) Other projects utilizing in vitro proteome |
| client | Medical research institutes, pharmaceutical companies, bio ventures, diagnostics manufacturers |
| Financial Institutions | Mizuho Bank, Mitsubishi UFJ Bank, SBI Sumishin Net Bank, Shoko Chukin Bank, Japan Finance Corporation |
| Research Ethics Review Committee | Established on April 4, 2008 (Research Ethics Review Committee Reporting System https://rinri.niph.go.jp) |
| Company URL | https://proteo-bridge.co.jp/ |
Research Ethics Review Committee
We have established an ethics review committee based on the “Ethical Guidelines for Medical Research Involving Human Subjects” joint guidelines by the Ministry of Health, Labour and Welfare and the Ministry of Education, Culture, Sports, Science and Technology, and the “Ethical Guidelines for Human Genome and Genetic Analysis Research” joint guidelines by the Ministry of Health, Labour and Welfare, the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Economy, Trade and Industry’s “Guidelines for the Use of Human ES Cells” and “Guidelines for Research on the Creation of Germ Cells from Human iPS Cells or Human Tissue Stem Cells.”
| Name of the Committee | Research Ethics Committee |
| Installation date | April 4, 2018 |
| Installation type | Single |
| Number of Committee Members | 5 people (4 men/1 woman) including 4 external members |
Collaboration with the National Institute of Advanced Industrial Science and Technology
Our company is a venture company spun off from the National Institute of Advanced Industrial Science and Technology (AIST). We have been granted exclusive licenses and exclusive licenses for the intellectual property rights invented by Naoki Goshima, Executive Vice President and CSO.
In addition, we have received tangible and intangible cooperation from the AIST Group.
History
| 2016年 | April | Adopted by the AIST Startup Development Strategy Task Force and began development towards becoming a venture |
| 2018年 | January | Founded Exclusive license agreement signed with the National Institute of Advanced Industrial Science and Technology |
| July | Cooperative research agreement signed (Tohoku University, Santen Pharmaceuticals) “Comprehensive basic research aimed at elucidating the pathology of glaucoma” | |
| November | Concluded technical advisory contract with Professor Shinichi Sato and Lecturer Ayumi Yoshizaki of the Department of Dermatology, Graduate School of Medicine, The University of Tokyo | |
| 2019年 | February | Selected for the Next Generation Innovation Creation 2020 Grant (Tokyo Metropolitan Government) Selected for the Incubation Venture Grant (Ogasawara Toshiaki Memorial Foundation) |
| November | Cooperative research agreement signed (Kitasato University, Astellas Pharma) “Development of a new measurement system for autoantibodies involved in diseases and identification of new autoantibodies” | |
| 2020年 | April | Cooperative research agreement signed (Maruho Co., Ltd.) “Joint research related to the development of drugs to treat skin diseases” |
| December | Cooperative research agreement signed (Department of Dermatology, Graduate School of Medicine, The University of Tokyo) “Research into the analysis and utilization of antibodies in human diseases” | |
| 2021年 | October | A third-party allotment of new shares of 30.15 million yen was implemented, with Fushimi Pharmaceutical Co., Ltd. (Head office: Marugame City, Kagawa Prefecture) as the underwriter. |
| December | Third-party allotment of new shares to the National Institute of Advanced Industrial Science and Technology Launch of research test A-Cube® (Scleroderma Set, Myositis Set, Integrated Set) | |
| 2022年 | May | Cooperative research agreement concluded (Department of Dermatology, University of Tokyo Hospital and Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences) “Research aimed at establishing a comprehensive autoantibody measurement system for Japanese people and improving its accuracy” |
| June | Implemented a third-party allotment of new shares of 180 million yen (Series A procurement) with Sparx Asset Management Co., Ltd. as the underwriter. | |
| August | Selected for the “Go-tech” research and development support program for growth-oriented small and medium-sized enterprises (Ministry of Economy, Trade and Industry) | |
| 2023年 | March | Patent application with Hiroshima University regarding a method for diagnosing autoimmune subfornical organ disease |
| April | Patent application with the University of Tokyo regarding a method for detecting systemic scleroderma | |
| May | Cooperative research agreement signed (Hiroshima University Graduate School of Medicine, Department of Pediatrics) “Analysis of specific antibodies against circumventricular organs in relation to the onset of ROHHAD syndrome and elucidation of the onset mechanism” Cooperative research agreement signed (Department of Neurology, University of Tokyo Hospital) “Molecular pathological genetic analysis research to clarify the pathological mechanism of peripheral neuromuscular diseases” | |
| August | Launch of HuPEX® comprehensive protein array analysis service | |
| October | Obtained ISO9001 certification (A-Cube® research testing, HuPEX® comprehensive protein array contract analysis) Cooperative research agreement signed (Kagoshima University Hospital, Department of Neurology) “Research into identifying the causes of encephalitis/encephalopathy and elucidating their pathology” | |
| 2024年 | March | Raised 100 million yen in loans with stock acquisition rights from Shoko Chukin Bank |
| June | Cooperative research agreement signed (Department of Allergy and Rheumatology, Faculty of Medicine, The University of Tokyo) “Development of a new autoantibody detection system for autoimmune diseases” | |
| July | Cooperative research agreement signed (Hokkaido University Institute for Genetic Medicine) “Development of preventive treatments targeting microinflammation that leads to disease” | |
| August | Cooperative research agreement concluded (Department of Dermatology, University of Tokyo Hospital and Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences) “Acquisition of data on autoantibodies from healthy Japanese subjects and establishment of reference ranges” | |
| October | Cooperative research agreement concluded (Kyoto University Hospital, Department of Immunology and Rheumatology) “Identification of new autoantibodies in lupus enteritis” | |
| November | Received the Tokyo Venture Technology Award Special Prize (Research and Testing A-Cube®) | |
| December | Cooperative research agreement concluded (Department of Allergy and Rheumatology, Faculty of Medicine, The University of Tokyo) “Research into autoantibodies related to rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)” | |
| 2025年 | January | Winner of the SMBC Venture Capital Award at the NIKKEI THE PITCH Block Competition hosted by the Nihon Keizai Shimbun (Research Test A-Cube®) |
Access
○Train information
3 minutes walk from Telecom Center Station on the Yurikamome Line
15 minutes walk from Tokyo Teleport Station on the Rinkai Line
○Bus information
Take Toei Bus [Umi 01] from “Tokyo Teleport” Station on the Rinkai Line or “Monzen-Nakacho” Station on the Tozai and Oedo Subway Lines
○From Haneda Airport
Take the monorail from the airport
→ Transfer to the Rinkai Line at Tennozu Isle Station
→ 15 minutes walk from Tokyo Teleport Station
Careers
We are not currently recruiting. |
Privacy Policy
Privacy Policy
Proteobridge Inc. operates a medical and health-related business that focuses on drug discovery research and development support and research testing. The company’s management philosophy is “Building a bridge of proteomics to a healthier tomorrow.”
We are committed to safeguarding the personal information of our customers and all individuals associated with our company. We will make every effort to protect personal information in accordance with the following policy.
1. Notification or public announcement of the purpose of use of personal information
(1) When obtaining personal information directly from customers in writing, we will notify them of the purpose of use each time. Furthermore, personal information entered on this website will not be used for any purpose other than responding to inquiries and sending materials, etc. to the person who entered it.
(2) When personal information is acquired through means other than those mentioned in (1) above, it will be handled exclusively for purposes with below. For specific personal information, it will be handled within the scope of administrative tasks where the personal number can be used.
① The purpose of using of personal information on subjects and contractors of contracted testing services (“Contracted Services”) obtained through the contracted testing services
・Carrying out inspections, measurements, analyses, records, and management related to the commissioned work
・Handling reports, requests, and inquiries required for the performance of the commissioned work
・Soliciting, selling, providing, and shipping products or services (“Products, etc.”) of our company and third parties
・Advertising or promotion of products, etc. of our company and third parties (including sending emails and other advertising materials)
・Billing and charge calculations
・Identity verification
・Conducting surveys, sweepstakes, and campaigns
・Research, statistics, and analysis of marketing data
・Development of new products, etc.
・System maintenance, management, and troubleshooting
・Requests for research cooperation
・そOther purposes individually specified for each of our services
② Purpose of use of shareholder’s personal information
・Fulfilling our obligations under the Companies Act and other laws and regulations and responding to the shareholders’ rights
・Managing shareholders
・Sending notices of general shareholders’ meetings, business reports, and other distribution materials
・Implementing various measures to build smooth relationships with shareholders
③ Purpose of use of personal information of job applicants
・Review and decision on employment
・Contact regarding employment
・Onboarding procedures for new employees
④ Purpose of use of employee personal information
・Management of work, salary payment, personnel affairs, evaluation, skills development, welfare, health and safety, etc.
・Contacting and providing information to labor unions, health insurance associations, and related companies
・Notification and reporting to government agencies
⑤ Purpose of use of personal information on former employees
・Payment of pensions, etc., provision of company information, contact as necessary for social gatherings, management of retirees, etc.
⑥ Purpose of use of personal information of individuals who make requests for disclosure or complaints regarding personal information
・Investigations to respond to requests, complaints, etc.
・Verification of the individual or representative
・Sending responses and making necessary contact
・Management of requests, complaints, etc. regarding personal information
⑦ Purpose of use of personal information related to our business partners
・Management of contracts and liabilities, communication of information necessary for business, etc.
2.Provision of personal information to third parties
We do not provide personal information to third parties without the individual’s consent, except as required by law or in one of the following cases.
① When requested to disclose personal information by a court, the public prosecutor’s office, the police, the tax office, the bar association, or an institution with equivalent authority
② When disclosed to financial institutions, credit card companies, collection agencies, or other businesses that handle settlements or act on behalf of financial institutions in order to settle fees or other amounts owed to us by the customer
③ When entrusting all or part of our business to a third party (however, this is limited to those that meet the evaluation criteria set by our company)
④ When disclosed to a person who has a confidentiality obligation to us
⑤ When necessary to exercise our rights
⑥ When disclosed to a person who will take over the business in the event of a merger, business transfer, company split, or other business succession
⑦ Other cases specified individually for each of our services
3.Requests for disclosure of personal information, filing of complaints
We will respond to requests for disclosure, etc., from the individual or their representative regarding retained personal data for which we have the authority to respond (“notification of purpose of use,” “disclosure,” “correction, addition or deletion of content,” “suspension of use, erasure, and suspension of provision to third parties”). However, information entrusted to us by customers in the course of contracted business, as well as the results of inspections, tests, and analyses, may not be considered “retained personal data” by our company. Please check with the entrusting party, etc. regarding these “requests for disclosure, etc.” In addition, when responding to the above, we will verify your identity using a method specified by our company. For contact information and methods for inquiries regarding the above, please see 5 below.
4.Matters concerning anonymously processed information
(1) Creation of anonymously processed information
Currently, we have not created anonymously processed information. In the event that we create anonymously processed information (information that has been processed so that a specific individual cannot be identified and cannot be restored), we will take the following measures.
・Appropriate processing must be carried out in accordance with the standards prescribed by law.
・Safety management measures must be taken to prevent the leakage of information deleted from personal information used to create the anonymously processed information and information regarding the processing method in accordance with the standards prescribed by law.
・Items of information about individuals contained in the anonymously processed information must be made public in accordance with the standards prescribed by law.
・No matching with other information must be made with the aim of identifying individuals related to the personal information from which the anonymously processed information was created.
(2) Provision of anonymously processed information
When the Company provides anonymously processed information to a third party, the items of personal information contained in the anonymously processed information and the method of providing the anonymously processed information are as follows.
① Personal information included in anonymously processed information provided to third parties
・Gender, age, disease name, antibody detection images and quantitative data
② Method of providing anonymously processed information
・Provision via a server with appropriate access restrictions and management
・Provision via other methods or external storage media that take security measures (encryption and password settings) to prevent information leakage and theft
5.Contact Information
(1) By telephone
Proteobridge Co., Ltd. Business Management Department
TEL：03-6457-1600
10:00-17:00 (JST) (excluding weekends, national holidays, New Year’s holidays, and other designated holidays)
(2) By letter
2-3-26 Aomi, Koto-ku, Tokyo 135-0064
National Institute of Advanced Industrial Science and Technology,
Waterfront Center Main Building
Proteobridge Co., Ltd. Business Management Department
(3) By email
Personal information protection policy and complaint consultation desk
privacy@proteo-bridge.co.jp
(4) About visiting our company
Please note that we are unable to accept requests to visit our office in person.
(5) Company name, address, and name of representative
Proteobridge Co., Ltd.
7-26 Ariake 3-chome, Koto-ku, Tokyo
Ariake Frontier Building B, 9th floor
CEO: Kumagai Ryo
End
Site Policy (Terms of Use)
Formulated January 5, 2018
This website was established and is operated by Proteobridge Corporation (hereinafter referred to as “our company”). Please read the following terms of use carefully before using this site. Once you have started using this site, we will regard you as having agreed to the following terms and conditions.
We will change the Terms of Use as necessary and display them on this site. Please be sure to check the latest information when using this site.
Disclaimer
Although we make every effort to ensure that the contents of this website are accurate and up-to-date, we do not guarantee or assume any responsibility that they are accurate, complete, or reliable, that they are suitable for your purposes, or that access to this website is free from errors or the risk of computer virus contamination. We shall not be liable for any damages incurred as a result of accessing or being unable to access this website, or as a result of trusting the contents of this website.
Changes to content and service interruptions
We may add, change, or delete information on this website without prior notice. We may also close this website without prior notice.
Copyright
All text, illustrations, logos, photographs, videos, software, and other information posted on this website are copyrighted by our company or a third party.
Except for personal use or other uses permitted by copyright law, you may not use this information (including copying, modifying, distributing, publicly transmitting, etc.) without the prior permission of the copyright holder. In addition, the names of our products or services posted on our website are trademarks or registered trademarks of our company or a third party.
Links
We are not responsible for any third-party websites that are linked to this site or for any third-party websites to which this site has links. If you move from this site to a third-party website, you do so at your own risk. If you wish to link to this site, please obtain our prior consent.
Product and medical information
The information on this website is intended for medical professionals (doctors, pharmacists, nurses, etc.) in Japan and researchers of autoantibodies, and contains information to ensure the proper use of our products and contract research services. Therefore, it is not intended to provide information to the general public or medical professionals overseas.
Personal Information
We will handle any personal information obtained through the use of this website appropriately in accordance with our “Personal Information Protection Policy (https://proteo-bridge.co.jp/company)”.
In the event of a violation of these terms
If you do not comply with these terms, we may take measures to prevent you from using this website in the future. We cannot accept any responsibility for any inconvenience or damage caused to you by taking such measures. If you cause damage to us as a result of your violation of these terms, you must compensate us for all losses, expenses, damages and costs, including reasonable attorney’s fees.
Governing Law
These Terms of Use shall be governed by and construed in accordance with the laws of Japan. Any disputes arising from these Terms of Use shall be submitted to the Tokyo District Court as the court of first instance with exclusive jurisdiction.
Access history
This site records and analyzes access history in order to understand how users use this site. This information is not used to obtain personal information about users.
Required features
This site uses Secure Socket Layer (SSL), Http-Cookies, JavaScript, and style sheets. Please enable these functions in your browser settings before using this site. If you disable these functions in your browser settings, you may not be able to use some of the services on this site.
End
Information Security Policy
January 1, 2025
Proteobridge Corporation is a bio-venture company from the National Institute of Advanced Industrial Science and Technology (AIST), with a social mission to improve medical care and health based on the management philosophy of “Building proteomic bridge to a healthy tomorrow”. Our core business is drug discovery, research and development support, and research testing, with a focus on blood autoantibody analysis.
In order to fulfil our mission, we ensure the confidentiality and integrity of all information handled in our business, including personal information. We must also ensure the availability of valuable information assets, including autologous antibody data provided to us, for research and development. We also consider our social responsibility to ensure information security and cyber security in preparation for various threats, such as unauthorised access and computer viruses that aim to falsify or leak information. For address the aforementioned issues, we have established an information security management system (ISMS) in accordance with the requirements and our information security policy. We are committed to the continuous improvement of this system so that we can become a company trusted by our customers.
1.We are committed to adhering to all applicable guidelines, laws, regulations, and contractual requirements related to information security. We also uphold the standards we have established internally.
2.The following points will be addressed through the operation of ISMS:
We are committed to using and providing accurate and reliable information, while maintaining the confidentiality of the information used in our business.
We implement the necessary information security controls to protect our customers and our business from cyber security threats.
3.We have a governance structure in place that allows us to regularly monitor the status of information security management and implement necessary security measures. This is achieved through regular meetings of the Information Security Committee, which includes the chief executive officer.
4.We conduct regular audits to ensure that the relevant guidelines, laws, regulations and contractual requirements related to information security, as well as the standards we have established, are functioning effectively.
5.We are committed to the continuous professional development of our employees, and as such we provide regular training to enhance their information security literacy.
6.When we outsource operations that handle information assets, we will conduct a full examination of the outsourced company’s suitability and stipulate in the contract or otherwise that it will maintain the level of security that we require.
7.This policy will be communicated to all employees and partners, and every effort will be made to implement.